Spots Global Cancer Trial Database for immune checkpoint
Every month we try and update this database with for immune checkpoint cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitor | NCT03590808 | Influenza Solid Carcinoma | Influenza vacci... | 20 Years - | Seoul National University Hospital | |
| Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype | NCT03718767 | Glioma Glioblastoma High Grage Glio... Low Grade Gliom... Malignant Gliom... | Nivolumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia | NCT02733042 | Lymphoma Leukemia, Lymph... | Durvalumab Lenalidomide Rituximab Ibrutinib Bendamustine | 18 Years - | Celgene | |
| PBMC-based Leukocyte Immunotherapy | NCT06172894 | Advanced Solid ... | APN401 | 18 Years - | invIOs GmbH | |
| Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) | NCT03354962 | Melanoma | Nivolumab + Ipi... Combined treatm... | 18 Years - | Institut Claudius Regaud | |
| Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) | NCT03354962 | Melanoma | Nivolumab + Ipi... Combined treatm... | 18 Years - | Institut Claudius Regaud | |
| Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype | NCT03718767 | Glioma Glioblastoma High Grage Glio... Low Grade Gliom... Malignant Gliom... | Nivolumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma | NCT03958045 | Small Cell Lung... | Rucaparib and N... | 18 Years - | University of Kentucky | |
| Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ | NCT06218303 | Ductal Carcinom... | MUC1 Peptide Va... Hiltonol® Aromatase Inhib... | 18 Years - | University of Pittsburgh | |
| PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer | NCT02793856 | Metastatic Non-... | Cyclophosphamid... PD-1 Knockout T... | 18 Years - 70 Years | Sichuan University | |
| The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial | NCT03158935 | Advanced Ovaria... Malignant Melan... | Cyclophosphamid... Fludarabine Pembrolizumab Tumor-Infiltrat... Interleukin-2 (... | 18 Years - | University Health Network, Toronto | |
| PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer | NCT03081715 | Esophageal Canc... | PD-1 Knockout T... | 18 Years - 80 Years | Hangzhou Cancer Hospital | |
| PBMC-based Leukocyte Immunotherapy | NCT06172894 | Advanced Solid ... | APN401 | 18 Years - | invIOs GmbH | |
| Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ | NCT06218303 | Ductal Carcinom... | MUC1 Peptide Va... Hiltonol® Aromatase Inhib... | 18 Years - | University of Pittsburgh | |
| The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial | NCT03158935 | Advanced Ovaria... Malignant Melan... | Cyclophosphamid... Fludarabine Pembrolizumab Tumor-Infiltrat... Interleukin-2 (... | 18 Years - | University Health Network, Toronto |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
